OnKure Therapeutics, Inc. - Class A Common Stock (OKUR)
4.2100
-0.0100 (-0.24%)
NASDAQ· Last Trade: Jul 16th, 1:52 AM EDT
Detailed Quote
Previous Close
4.220
Open
4.230
Bid
4.130
Ask
4.400
Day's Range
4.160 - 4.427
52 Week Range
1.910 - 5.380
Volume
79,879
Market Cap
141.69M
PE Ratio (TTM)
0.0452
EPS (TTM)
93.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
470,777
Chart
About OnKure Therapeutics, Inc. - Class A Common Stock (OKUR)
OnKure Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. The company specializes in designing and advancing small molecule drugs that target specific biological pathways associated with tumor growth and progression. With a commitment to addressing unmet medical needs, OnKure aims to improve the effectiveness and safety of cancer treatment through its proprietary drug development platform, enabling it to identify and optimize potential therapeutic candidates for various types of cancer. Their research and clinical efforts are geared towards bringing novel and effective solutions to patients facing challenging oncological conditions. Read More
OnKure Therapeutics (NASDAQ:OKUR) used a scientific webcast to outline its strategy for developing mutant-selective PI3Kα inhibitors, emphasizing allosteric inhibition as a potential way to improve efficacy and tolerability in cancer and vascular anomalies.
Nick Saccomano, president and chief execu
OnKure Therapeutics (OKUR) reported Q2 2025 EPS of -$1.14, beating estimates, with no revenue. Stock rose 1.5% after hours. Clinical progress on OKI-219 cancer drug remains on track for Q4 2025 data.
OnKure Therapeutics has garnered attention following its merger with Reneo Pharmaceuticals and a $65 million private placement. Oppenheimer initiated coverage with an Outperform rating, highlighting the potential of OKI-219 in targeting breast cancer mutations.
